Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Natera","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Natera Enters Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Natera","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natera and Genentech Initiate Phase III Trial Using Signatera as a Companion Diagnostic for Atezolizumab in Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Natera

    Menu

    Natera

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Natera

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Natera and Genentech Initiate Phase III Trial Using Signatera as a Companion Diagnostic for Atezolizumab in Muscle-Invasive Bladder Cancer

              Details:

              First patient has been screened in a new phase III clinical trial that uses Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma patients eligible for investigational treatment with Genentech’s cancer immunotherapy drug Tecentriq.

              Lead Product(s): Atezolizumab

              Therapeutic Area: Oncology Product Name: Tecentriq

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Genentech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Natera

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Natera Enters Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

              Details:

              The collaboration is focused on a investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali®), a CDK4/6 inhibitor, for the treatment of ER-positive breast cancer (LEADER).

              Lead Product(s): Ribociclib,Hormone therapy

              Therapeutic Area: Oncology Product Name: Kisqali

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Massachusetts General Hospital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY